WARNING
| Use in Pregnancy:
When used in pregnancy during the second and third
trimesters, ACE inhibitors can cause injury and even
death to the developing fetus. When pregnancy is detected,
benazepril HCl should be discontinued as soon as possible.
See WARNINGS, Fetal/Neonatal Morbidity and Mortality. |
DESCRIPTION
Benazepril HCl is a white to off-white crystalline
powder, soluble (>100 mg/ml) in water, in ethanol, and
in methanol. Benazepril's chemical name is 3-[[1-(ethoxy-carbonyl)-3-phenyl-(1S)-propyl]amino]-2,
3, 4, 5-tetrahydro-2-oxo-1H-1-(3S)-benzazepine-1-acetic
acid monohydrochloride. Its empirical formula is C24H28N2O5·HCl,
and its molecular weight is 460.96.
Benazeprilat, the active metabolite of benazepril, is a
non-sulfhydryl Angiotensin-converting enzyme inhibitor.
Benazepril is converted to Benazeprilat by hepatic cleavage
of the ester group.
Lotensin is supplied as tablets containing 5 mg, 10 mg,
20 mg, and 40 mg of benazepril for oral administration.
The inactive ingredients are cellulose compounds, colloidal
silicon dioxide, crospovidone, hydrogenated castor oil (5
mg, 10 mg, and 20 mg tablets), iron oxides, lactose, magnesium
stearate (40 mg tablets), polysorbate 80, propylene glycol
(5 mg and 40 mg tablets), starch, talc, and titanium dioxide.
| |
